IP Verse

Rapamycin Derivative For Treating Pancreas Cancer - EP3342411

The patent EP3342411 was granted to Novartis on Aug 21, 2019. The application was originally filed on Feb 18, 2002 under application number EP18155724A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3342411

NOVARTIS
Application Number
EP18155724A
Filing Date
Feb 18, 2002
Status
Opposition Rejected
Dec 18, 2023
Grant Date
Aug 21, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ARROW GENERIQUESJun 1, 2020KONIGERADMISSIBLE
TEVA PHARMACEUTICALSMay 19, 2020GREINERADMISSIBLE
ZENTIVA KSMay 11, 2020BIRD & BIRDADMISSIBLE
GENERICS UKMay 5, 2020ELKINGTON AND FIFEWITHDRAWN
PUREN PHARMAApr 29, 2020KONIGERWITHDRAWN
ETHYPHARMFeb 14, 2020LLRADMISSIBLE
BIOGARANSep 30, 2019CASALONGAADMISSIBLE
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELAug 27, 2019MAIWALDWITHDRAWN
ACCORD HEALTHCAREAug 23, 2019PLOUGMANN VINGTOFTWITHDRAWN
STADA ARZNEIMITTELAug 22, 2019HAMM & WITTKOPPADMISSIBLE

Patent Citations (54) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0296110
DESCRIPTIONEP0520722
DESCRIPTIONEP0564409
DESCRIPTIONEP0566226
DESCRIPTIONEP0769947
DESCRIPTIONEP0787722
DESCRIPTIONEP0837063
DESCRIPTIONGB2177700
DESCRIPTIONUS4100274
DESCRIPTIONUS4636505
DESCRIPTIONUS4659516
DESCRIPTIONUS5010099
DESCRIPTIONUS5362718
DESCRIPTIONUS5747498
DESCRIPTIONUS5843901
DESCRIPTIONWO0009495
DESCRIPTIONWO0027819
DESCRIPTIONWO0027820
DESCRIPTIONWO0037502
DESCRIPTIONWO0059509
DESCRIPTIONWO9409010
DESCRIPTIONWO9410202
DESCRIPTIONWO9503283
DESCRIPTIONWO9516691
DESCRIPTIONWO9630347
DESCRIPTIONWO9633980
DESCRIPTIONWO9641807
DESCRIPTIONWO9702266
DESCRIPTIONWO9730034
DESCRIPTIONWO9738983
DESCRIPTIONWO9749688
DESCRIPTIONWO9810767
DESCRIPTIONWO9811223
DESCRIPTIONWO9835958
DESCRIPTIONWO9903854
DESCRIPTIONWO9917804
OPPOSITIONEP1363267
OPPOSITIONEP2275103
OPPOSITIONEP2783686
OPPOSITIONEP3143995
OPPOSITIONEP3342411
OPPOSITIONEP3345602
OPPOSITIONEP3351246
OPPOSITIONEP3406249
OPPOSITIONGB104072
OPPOSITIONGB124957
OPPOSITIONUS876165
OPPOSITIONWO0151049
OPPOSITIONWO02066019
OPPOSITIONWO02080975
OPPOSITIONWO9409010
OPPOSITIONWO9747317
SEARCHWO9409010
SEARCHWO9747317

Non-Patent Literature (NPL) Citations (57) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CLARK, Breast Cancer Research Treatment, (19970000), vol. 46, page 255-
DESCRIPTION- F. YUAN et al., Proc. Natl. Acad. Sci. USA, (19961200), vol. 93, pages 14765 - 14770-
DESCRIPTION- J. MORDENTI et al., Toxicologic Pathology, (19990000), vol. 27, no. 1, pages 14 - 21-
DESCRIPTION- M. PREWETT et al., Cancer Research, (19990000), vol. 59, pages 5209 - 5218-
DESCRIPTION- M. S. O'REILLY et al., Cell, (19940000), vol. 79, pages 315 - 328-
DESCRIPTION- M. S. O'REILLY et al., Cell, (19970000), vol. 88, pages 277 - 285-
DESCRIPTION- Z. ZHU et al., Cancer Res., (19980000), vol. 58, pages 3209 - 3214-
OPPOSITION- ALEXANDRE J et al., "La rapamycine et le CCI-779", Bull Cancer, (19990000), vol. 86, no. 10, pages 808 - 811, XP002201077-
OPPOSITION- Anonymous, "AR42J ATCC ® CRL-1492™", ATCC - Product Sheet, (2013), pages 1 - 3, URL: www.atcc.org, XP055699761-
OPPOSITION- Anonymous, "Neuroendocrine tumours (NETs)", Cancer Research, (2015), URL: https://www.cancerresearchuk.org/, XP055699749-
OPPOSITION- Anonymous, "Types of Pancreatic Cancer", Cancer Research UK, (20140524), URL: https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades/types, XP055699750-
OPPOSITION- Antwi et al., "32. Cancer of the Pancreas", Antwi et al., Schottenfeld and Fraumeni, Cancer Epidemiology and Prevention, 4th ed., Oxford, (20180000), pages 611 - 612, XP055705254-
OPPOSITION- BEUVINK et al., "1972 Antitumor Activity of RAD001, an Orally Active Rapamycin Derivative", 92nd Proceedings of the American Association for Cancer Research, (20010324), vol. 42, page 366, XP001093826-
OPPOSITION- BEUVINK et al., "ANTITUMOR ACTIVITY OF RAD001, AN ORALLY ACTIVE RAPAMYCIN DERIVATIVE", Proceedings of the American Association for Cancer Research, (20010000), vol. 42, XP001093826-
OPPOSITION- Beuvink I. et al, "1972 Antitumor Activity of RAD001, an Orally Active Rapamycin Derivative", 92nd Annual Meeting Proc Am Assoc Cancer Research, (20010324), vol. 42, XP001093826-
OPPOSITION- CROWE et al., "Absorption and Intestinal Metabolism of SDZ-RAD and Rapamycin in Rats", Drug Metabolism and Disposition, (19990000), vol. 27, no. 5, pages 627 - 635, XP055449375-
OPPOSITION- DUMONT, "Everolimus Novartis", Curr Opin Investig Drugs, (20010000), vol. 2, no. 9, pages 1220 - 1234, XP055639440-
OPPOSITION- Dumont, "Everolimus Novartis", Curr Opin Investig Drugs, (20010900), vol. 21, no. 9, pages 1220 - 1234, XP055639440-
OPPOSITION- DUMONT F. J. ET AL, "Everulimus Novartis", Current Opinion in Investigational Drugs, (200109), vol. 2, no. 9, pages 1220 - 1234, XP055699747-
OPPOSITION- EMA, "Afinitor 2.5 mg tablets Afinitor 5 mg tablets Afinitor 10 mg tablets", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, pages 1 - 49-
OPPOSITION- ENG et al., "ACTIVITY OF RAPAMYCIN (AY-22,989) AGAINST TRANSPLANTED TUMORS", The Journal of Antibiotics, (19840000), vol. 37, no. 10, pages 1231 - 1237, XP001098253-
OPPOSITION- GIBBONS et al., "THE EFFECT OF CCI-779, A NOVEL MACROLIDE ANTI-TUMOR AGENT, ON THE GROWTH OF HUMAN TUMOR CELLS IN VITRO AND IN NUDE MOUSE XENOGRAFTS IN VIVO", Proceedings of the American Association for Cancer Research, (19990000), vol. 40, XP001071222-
OPPOSITION- Grewe et al., "Regulation of Cell Growth and Cyclin D1 Expression by the Constitutively Active FRAP-p70 s6K Pathway in Human Pancreatic Cancer Cells", Cancer Research, (19990000), vol. 59, pages 3581 - 3587, XP055701509-
OPPOSITION- GREWE et al., "Regulation of Cell Growth and Cyclin D1 Expression by the Constitutively Active FRAP-p70s6K Pathway in Human Pancreatic Cancer Cells", Cancer Research, (19990801), vol. 59, no. 15, pages 3581 - 3587, XP055701509-
OPPOSITION- GUBA et al., Chirurgisches Forum, (20010000), vol. 30, pages 37 - 39-
OPPOSITION- HAMM et al., "Das primäre Non-Hodgkin-Lymphom des Pankreas", Der Chirurg, (19980300), vol. 69, no. 3, pages 301 - 305, XP055701518-
OPPOSITION- HOSOI et al., "Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells", Cancer Res., (19990215), vol. 59, no. 4, pages 886 - 94, XP001154916-
OPPOSITION- MCMAHON et al., "High-throughput analysis of everolimus (RADOOl) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction syste", Rapid Communications in Mass Spectrometry, (20000928), vol. 14, no. 21, pages 1965 - 1971, XP055639343-
OPPOSITION- "Pancreatic Tumors", Beers et al., The Merck Manual of Diagnosis and Therapy, 17th ed., Whitehouse Station , N.J., (19990000), pages 330 - 335, XP055705273-
OPPOSITION- R. E. MORRIS, "Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides", Transplantation Reviews, (19920000), vol. 6, no. 1, pages 39 - 87, XP009110318-
OPPOSITION- SORBERRA et al., "SDZ-RAD - Immunosuppressant", Drugs of the Future, (19990000), vol. 24, no. 1, pages 22 - 29, XP055640391-
OPPOSITION- SHAH et al., "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", Journal of Surgical Research, (20001102), vol. 97, no. 2, pages 123 - 130, XP029590080
OPPOSITION- SHAH et al., "FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation", Journal of Surgical Research, (20010000), vol. 97, doi:10.1006/jsre.2001.6145, pages 123 - 130, XP001154435
OPPOSITION- SHAH et al., "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", Journal of Surgical Research, (20010000), vol. 97, pages 123 - 130, XP001154435
OPPOSITION- SHAH et al., "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", Journal of Surgical Research, (20010000), vol. 97, pages 123 - 130, XP029590080
OPPOSITION- SHIMUL, "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", Journal Of Surgical Research, vol. 97, no. 2, doi:10.1006/jsre.2001.6145, pages 123 - 130, XP029590080
OPPOSITION- SEUFFERLEIN et al., "Constitutive activation of p70s6k in human pancreatic cancer cell lines bearing activating Ki-ras mutations", Gastroenterology, (19980415), vol. 114, page A496, XP027466913
OPPOSITION- Seufferlein T. et al, "Constitutive activation of p70s6k in human pancreatic cancer cell lines bearing activating Ki-ras mutations", Gastroenterology, (19980415), vol. 114, no. 4, page A496, XP027466913
OPPOSITION- SEDRANI, "Chemical modification of rapamycin: the discovery of SDZ RAD", Transplant Proc, (19980000), vol. 30, no. 5, doi:10.1016/S0041-1345(98)00587-9, pages 2192 - 4, XP000925138
OPPOSITION- HIDALGO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20000000), vol. 19, doi:10.1038/sj.onc.1204091, pages 6680 - 6686, XP009002368
OPPOSITION- HIDALGO et al., "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20000000), vol. 19, pages 6680 - 6686, XP002323912
OPPOSITION- HIDALGO et al., "THE RAPAMYCIN-SENSITIVE SIGNAL TRANSDUCTION PATHWAY AS A TARGET FOR CANCER THERAPY", Oncogene, (20001201), vol. 19, no. 56, pages 6680 - 6686, XP009002368
OPPOSITION- HIDALGO, "The rapamycin sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (20000000), doi:10.1038/sj.onc.1204091, pages 6680 - 6686, XP009002368
OPPOSITION- NEUHAUS et al., "mTOR Inhibitors: An Overview", Liver Transplantation, (20010601), vol. 7, no. 6, pages 473 - 484, XP055542856
OPPOSITION- HUAN G et al., "MECHANISMS OF RESISTANCE TO RAPAMYCINS", Drug Resistance Updates, (20010000), vol. 4, pages 378 - 391, XP001094520
OPPOSITION- HUANG et al., "Mechanisms of resistance to rapamycins", Drug Resistance Updates, (20011200), vol. 4, no. 6, pages 378 - 391, XP001094520
OPPOSITION- HUANG et al., "Mechanisms of resistance to rapamycins", Drug Resist Updat., (20011200), vol. 4, no. 6, doi:10.1054/drup.2002.0227, pages 378 - 391, XP001094520
OPPOSITION- MAJEWSKI, "The Immunosuppressive Macrolide Rad Inhibits Growth Of Human Epstein- Barr Virus-Transformed B Lymphocytes In Vitro And In Vivo: A Potential Approach To Prevention And Treatment Of Posttransplant Lymphoproliferative Disorders", Proceedings Of The National Academy Of Sciences, vol. 97, no. 8, doi:10.1073/pnas.080068597, pages 4285 - 4290, XP001093844
OPPOSITION- ACHILLEFU et al., "NOVEL RECEPTOR-TARGETED FLUORESCENT CONTRAST AGENTS FOR IN VIVO TUMOR IMAGING", Investigative Radiology, (20000000), vol. 35, no. 8, pages 479 - 485, XP000978923
OPPOSITION- SCHUURMAN et al., "SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Synergism with Cyclosporine", Transplantation, (19970715), vol. 64, no. 1, pages 32 - 35, XP002048030
OPPOSITION- SCHULER et al., "SDZ RAD, a new rapamycin derivative", Transplantation, (19970000), vol. 64, no. 1, pages 36 - 42, XP002048032
OPPOSITION- SCHULER et al., "SDZ RAD, a new rapamycin derivative", Transplantation, (19970000), vol. 64, no. l, doi:10.1097/00007890-199707150-00008, pages 36 - 42, XP002048032
OPPOSITION- SCHULER, "SDZ RAD, A New Rapamycin Derivative", Transplantation, (19970000), vol. 64, doi:10.1097/00007890-199707150-00008, pages 36 - 42, XP002048032
SEARCH- Hidalgo Et Al., "The rapamycin sensitive signal transduction pathway as a target for cancer therapy", Oncogene, (2000), pages 6680 - 6686, URL: https://www.nature.com/articles/1204091, (20160509), XP055271130 [Y] 1-4 * page 6682, column 2, line 34 - line 42 *-
SEARCH- SHAH SHIMUL A ET AL, "FRAP-p70s6K Signaling Is Required for Pancreatic Cancer Cell Proliferation", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, (20001102), vol. 97, no. 2, doi:10.1006/JSRE.2001.6145, ISSN 0022-4804, pages 123 - 130, XP029590080 [Y] 1-4 * abstract *
SEARCH- SEUFFERLEIN T ET AL, "Constitutive activation of p70s6k in human pancreatic cancer cell lines bearing activating Ki-ras mutations", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 114, doi:10.1016/S0016-5085(98)82012-X, ISSN 0016-5085, (19980415), page A496, (19980415), XP027466913 [Y] 1-4 * abstract *
SEARCH- MAJEWSKI M ET AL, "THE IMMUNOSUPPRESSIVE MACROLIDE RAD INHIBITS GROWTH OF HUMAN EPSTEIN-BARR VIRUS-TRANSFORMED B LYMPHOCYTES IN VITRO AND IN VIVO: A POTENTIAL APPROACH TO PREVENTION AND TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (20000411), vol. 97, no. 8, doi:10.1073/PNAS.080068597, ISSN 0027-8424, pages 4285 - 4290, XP001093844 [Y] 1-4 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents